Characterization and preliminary anticonvulsant assessment of some 1,3,4-thiadiazole derivatives
Tóm tắt
The aim of this study was to perform the anticonvulsant screening test to select some 1,3,4-thiadiazole derivatives that could offer a distinct protection against maximal electroshock (MES)-induced seizures in mice. The screening test was performed for 13 tested compounds administered intraperitoneally (ip) in a constant dose of 300 mg/kg at various pretreatment times (i.e., 15, 30, 60 and 120 min) before the MES test. Additionally, the active compounds in the screening test were subsequently subjected to the MES test that allowed determination of their median effective doses (ED50 values). Only 2 out of 13 tested 1,3,4-thiadiazole derivatives i.e., 5-butyl-; and 5-heptyl-substituted in the heterocyclic ring 1,3,4-thiadiazoles produced a distinct protection against MES-induced tonic seizures in mice. Time-course and dose–response effects revealed that 5-butyl-2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole produced its maximum anticonvulsant action at 15 min after its ip administration to mice. In contrast, 5-heptyl-2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole exerted the maximum anticonvulsant action at 60 min after its ip administration to mice. The ED50 values for 5-butyl-2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole ranged between 247 and >500 mg/kg, whereas those for 5-heptyl-2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole ranged between 233 and >500 mg/kg. 5-Butyl-2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole and 5-heptyl-2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole could become potentially favorable antiepileptic drugs, if the results from this study were to be extrapolated into clinical settings.
Tài liệu tham khảo
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314–9.
Luszczki JJ, Cioczek JD, Kocharov SL, Andres-Mach M, Kominek M, Zolkowska D. Effects of three N-(carboxyanilinomethyl) derivatives of p-isopropoxyphenylsuccinimide on the anticonvulsant action of carbamazepine, phenobarbital, phenytoin and valproate in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol 2010;648(1–3):74–9.
Luszczki JJ, Kocharov SL, Czuczwar SJ. N-(anilinomethyl)-p-isopropoxyphenylsuccinimide potentiates the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model. Neurosci Res 2009;64(3):267–72.
Luszczki JJ, Kocharov SL, Czuczwar SJ. Effect of p-isopropoxyphenylsuccinimide monohydrate on the anticonvulsant action of carbamazepine, phenobarbital, phenytoin and valproate in the mouse maximal electroshock-induced seizure model. Pharmacol Rep 2010;62(1):194–202.
Luszczki JJ, Kominek M, Florek-Luszczki M, Tchaytchian DA, Kocharov SL, Zolkowska D. Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Epilepsy Res 2012;100(1–2):27–36.
Zolkowska D, Kominek M, Florek-Luszczki M, Kocharov SL, Luszczki JJ. Effects of N-(morpholinomethyl)-p-isopropoxyphenylsuccinimide on the protective action of different classical antiepileptic drugs against maximal electroshock-induced tonic seizures in mice. Pharmacol Rep 2013;65(2):389–98.
Loscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res 1991;8(2):79–94.
Brodie MJ, Schachter SC. 2nd ed. Fast facts epilepsy, Oxford: Health Press; 2001.
Matysiak J. Evaluation of antiproliferative effect in vitro of some 2-amino-5- (2,4-dihydroxyphenyl)-1,3,4-thiadiazole derivatives. Chem Pharm Bull 2006;54(7):988–91.
Matysiak J, Nasulewicz A, Pelczynska M, Switalska M, Jaroszewicz I, Opolski A. Synthesis and antiproliferative activity of some 5-substituted 2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles. Eur J Med Chem 2006;41(4):475–82.
Matysiak J, Niewiadomy A. Application of sulfinyl bis(2,4-dihydroxythiobenzoyl) in the synthesis of N-substituted 2-amino-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles. Synth Commun 2006;36(11):1621–30.
Matysiak J, Skrzypek A, Niewiadomy A. Synthesis and antifungal activity of novel 5-substituted 4-(1,3,4-thiadiazol-2-yl)benzene-1,3-diols. Heteroatom Chem 2010;21(7):533–40.
Skrzypek A, Matysiak J, Niewiadomy A, Bajda M, Szymanski P. Synthesis and biological evaluation of 1,3,4-thiadiazole analogues as novel AChE and BuChE inhibitors. Eur J Med Chem 2013;62:311–9.
Litchfield Jr JT, Wilcoxon F. A simplified method of evaluating dose–effect experiments. J Pharmacol Exp Ther 1949;96(2):99–113.
Stables JP, Kupferberg HJ. Molecular and cellular targets for anti-epileptic drugs. Chapter 16 – The NIH Anticonvulsant Drug Development (ADD) Program: preclinical anticonvulsant screening project. London: John Libbey; 1997.
White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH. Antiepileptic drugs. Discovery and preclinical development of antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.
Luszczki JJ, Wojda E, Andres-Mach M, Cisowski W, Glensk M, Glowniak K, et al. Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study. Epilepsy Res 2009;85(2–3):293–9.
Juszczak M, Matysiak J, Szeliga M, Pozarowski P, Niewiadomy A, Albrecht J, et al. 2-Amino-1,3,4-thiadiazole derivative (FABT) inhibits the extracellular signal-regulated kinase pathway and induces cell cycle arrest in human non-small lung carcinoma cells. Bioorg Med Chem Lett 2012;22(17):5466–9.
Juszczak M, Walczak K, Langner E, Karpinska M, Matysiak J, Rzeski W. Neuroprotective activity of 2-amino-1,3,4-thiadiazole derivative 4BrABT – an in vitro study. Ann Agric Environ Med 2013;20(3):575–9.